相关实验视频

Updated: May 3, 2026

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration

Published on: September 29, 2018

阿斯科布酸降低了膝关节整形术后的血头:来自随机对照试验的见解

Pooya Hosseini-Monfared¹, Alireza Mirahmadi¹, Mohammad Mehdi Sarzaeem²

¹Bone Joint and Related Tissues Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Arthroplasty today

|February 20, 2025

概括

外科手术期间使用的 Askorbic 酸在全膝关节整形术 (TKA) 后显著降低了血液损失. 这种抗氧化剂可能是TKA患者的血液保存策略的宝贵补充.

科学领域:

整形外科手术整形外科手术
生物化学生物化学
临床试验临床试验

背景情况:

在全膝关节整形术 (TKA) 后,流血是主要的并发症.
氧化应激和血液溶解有助于TKA后的血红蛋白下降.
亚酸 (维生素C) 是一种强大的抗氧化剂,有可能减轻这些影响.

研究的目的:

研究阿斯科布酸对TKA中血液损失的抗氧化作用.
为了评估 Askorbic 酸对患者在门诊 TKA 后报告的结果的影响.

主要方法:

进行了一项随机的双盲临床试验.
患者在外科手术前接受了静脉注射的 Askorbic 酸或安慰剂.
血液损失是通过血红蛋白下降量化;患者报告的结果 (牛津膝盖得分,WOMAC,KOOS,遗忘关节得分) 在6个月后被评估.

主要成果:

亚酸组在术后第一天显著降低了血红蛋白下降 (1.30 vs 1.91 g/dL,P < .001) 和总血液损失 (463.60 vs 732.11 mL,P < .001).
亚酸组中较少的患者达到血红蛋白下降的最低临床重要差异.
两组之间没有观察到术后功能或疼痛评分的显著差异.

结论:

在外科手术期间,使用 Askorbic 酸可在术后第一天减少大约 36% 的血液损失.
亚斯科布酸在TKA中显示出作为有效的血液保鲜剂的潜力.
建议在TKA的血液管理中考虑与特兰克萨姆酸一起使用 Askorbic 酸.

关键词:

抗氧化剂是一种抗氧化剂.亚斯科伯酸是什么? 亚斯科伯酸是一种失血是因为失去血液.整体膝关节关节整形手术

更多相关视频

Knee Arthrocentesis in Adults

Knee Arthrocentesis in Adults

Published on: February 25, 2022

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...